In Josh Safdie’s hectic new film, Timothée Chalamet plays a gifted Ping-Pong player who’s also a born performer.

If you've ever wondered who keeps things running seamlessly at the very top, look no further than Barbara Podbelsek, Senior ...

Mary Kay has tapped Grey New York as its global ad partner. The announcement precedes the launch of a master brand campaign, expected in late 2026. The agency won the cosmetics account after a ...

The influencers welcomed their second baby together, Kay's third, back in early October Courtesy of Kay and Tay Dudley Kay and Tay Dudley are enjoying their first holiday season as a family of five ...

Patient reported outcomes demonstrate favorable health-related quality of life metrics, fewer ICU stays and lower likelihood of rehospitalizations with Orca-T MENLO PARK, Calif., December 06, ...

SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced positive new data from its pipeline of allogeneic ...

Impressive results of a potential second-line combination treatment for multiple myeloma from the Majestec-3 trial of teclistamab plus daratumumab raised eyebrows at the American Society of Hematology ...

Orca-Q, Orca Bio’s second investigational allogeneic T-cell immunotherapy, showed low rates of acute and chronic GvHD, infections and non-relapse mortality with and without GvHD prophylaxis Orca-T ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced new data ...

Jane Krakowski will star as Mary Todd Lincoln through January 4, 2026. Jinkx Monsoon returns to star as Mary Todd Lincoln from January 8 through February 1, 2026. John Cameron Mitchell will star as ...

Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN ...